NeuroOne Reports Record $9.1 Million Revenue with 163% Growth Driven by Epilepsy Treatment Technology

NeuroOne Medical Technologies Corporation reported preliminary unaudited product revenue growth of 163% to a record $9.1 million for the fiscal year ended September 30, 2025, compared to $3.5 million in fiscal 2024. The medical technology company, which focuses on improving surgical care options for patients with neurological disorders, also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025.

Chief Executive Officer Dave Rosa attributed the substantial revenue growth to expanded customer interest and positive outcomes with the company's OneRF Ablation system for patients suffering from seizures associated with epilepsy. Rosa stated the company believes it is well positioned to expand use of the OneRF technology platform, indicating confidence in future growth prospects.

The company will host a virtual investor webinar to discuss business operations and recent updates, featuring presentations from both Rosa and Chief Financial Officer Ron McClurg. The webinar will include a question-and-answer session accessible through the provided webcast link and dial-in numbers.

This revenue milestone is significant for the neurological treatment sector as it demonstrates growing adoption of minimally invasive solutions for epilepsy management. The 163% growth rate substantially outpaces typical medical technology sector growth, suggesting strong market acceptance of NeuroOne's approach to treating neurological conditions.

For patients suffering from epilepsy and other neurological disorders, this development represents progress toward more effective treatment options. The company's focus on improving patient outcomes while potentially reducing procedural costs could have meaningful implications for healthcare systems and patients facing these challenging conditions.

The preliminary financial results are subject to completion of accounting and interim review procedures and may be adjusted. Complete financial results for the quarter are expected to be announced in December 2025. Investors should exercise caution as this preliminary information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles.

NeuroOne's technology platform addresses multiple neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. The company's progress in commercializing these solutions could potentially benefit millions of patients worldwide who struggle with these debilitating conditions.